Abstract:Atopic dermatitis (AD) is a common inflammatory skin condition occurring in both pediatric and adult patients. Pruritus is a clinical hallmark of the disease, and patients with AD often experience disruptions to their quality of life. The pathogenesis of AD is a complex and multifactorial interplay between genetic factors, epidermal barrier disruption, and immune dysregulation . Clinically, AD is characterized by pruritus, eczematous skin changes, and age-specific lesion distribution patterns. Infants and young children tend to have AD lesions on their face and extensor surfaces of their extremities while older children and adults tend to have AD lesions on flexural surfaces of their extremities. Many patients also experience a chronic and relapsing disease course. Due to the chronicity and severe pruritus, lesions often undergo secondary changes like lichenification. Patients with AD can experience a number of comorbidities including other atopic disease (i.e. allergic rhinitis, asthma), skin infections, cardiovascular, and neuropsychiatric illnesses. Management of AD depends on the severity of the disease as well as the distribution of the disease. Traditionally, treatment of AD included the use of moisturizers / emollients, topical corticosteroids or topical calcineurin inhibitors, or systemic therapy with non-selective immunosuppressants such as corticosteroids, cyclosporine , azathioprine, or similar. However, in the past decade, new biologic and small molecule drugs, both topical and systemic, have become important therapeutic options for AD patients, especially for those with moderate-to-severe disease. The development of these medications, following decades of research to better understand AD, are designed to specifically target various components of immune dysregulation and inflammation implicated in the pathogenesis of AD. Their successful development and deployment now allow for an exciting new era of treatment for individuals suffering from atopic dermatitis.

Revolutionizing the management of patients with atopic dermatitis: practical considerations

Atopic dermatitis: treatment and innovations in immunotherapy

Biologic drugs, a new therapeutic paradigm in moderate-severe atopic dermatitis

Emerging Treatments and New Vehicle Formulations for Atopic Dermatitis

Pharmacological Trends in the Management of Atopic Dermatitis: A Comprehensive Review

The paradigm shift in drug development for atopic dermatitis: Addressing the variables of the equation leading to disease modification

Updates in atopic dermatitis for the primary care physician: A review of advances in the understanding and treatment of atopic dermatitis

Emerging Biologic Therapies for the Treatment of Atopic Dermatitis

Topical Therapy for Atopic Dermatitis: What is New and the New Paradigm

Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs

At the Dawn of a Therapeutic Revolution for Atopic Dermatitis: An Interview with Dr Anne-Claire Fougerousse

Biologics and Oral Small-Molecule Inhibitors for Treatment of Pediatric Atopic Dermatitis: Opportunities and Challenges

A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis

Atopic dermatitis: new insight into the etiology, pathogenesis, diagnosis and novel treatment strategies

[What's new in dermatological treatment?]

Addressing Unmet Needs in Atopic Dermatitis: Evaluating Disease-Modifying Capabilities of Current and Emerging Therapies

Therapeutic management of atopic dermatitis

Unraveling Atopic Dermatitis: Insights into Pathophysiology, Therapeutic Advances, and Future Perspectives

[Severe atopic dermatitis in childhood in the era of personalized medicine]

Dual Biologic or Small Molecule Therapy in Patients with Atopic Dermatitis: A Systematic Review

Atopic dermatitis: a brief review of recent advances in management